Molecular Diversity

, Volume 22, Issue 2, pp 305–321 | Cite as

Synthesis and evaluation of bile acid amides of \(\alpha \)-cyanostilbenes as anticancer agents

  • Devesh S. Agarwal
  • Rajnish Prakash Singh
  • K. Lohitesh
  • Prabhat N. Jha
  • Rajdeep Chowdhury
  • Rajeev Sakhuja
Original Article


A series of amino-substituted \(\alpha \)-cyanostilbene derivatives and their bile acid (cholic and deoxycholic acid) amides were designed and synthesized. A comparative study on the anticancer and antibacterial activity evaluation on the synthesized analogs was carried against the human osteosarcoma (HOS) cancer cell line, and two gram −ve (E. coli and S. typhi) and two gram \(+\)ve (B. subtilis and S. aureus) bacterial strains. All the cholic acid \(\alpha \)-cyanostilbene amides showed an \(\hbox {IC}_{50}\) in the range 2–13 \(\upmu \hbox {M}\) against human osteosarcoma cells (HOS) with the most active analog (6g) possessing an \(\hbox {IC}_{50}\) of \(2\,\upmu \hbox {M}\). One of the amino-substituted \(\alpha \)-cyanostilbene, 4e, was found to possess an \(\hbox {IC}_{50}\) of \(3\,\upmu \hbox {M}\). An increase in the number of cells at the sub-\(\hbox {G}_{1}\) phase of the cell was observed in the in vitro cell cycle analysis of two most active compounds in the series (4e, 6g) suggesting a clear indication toward induction of apoptotic cascade. With respect to antibacterial screening, amino-substituted \(\alpha \)-cyanostilbenes were found to be more active than their corresponding bile acid amides. The synthesized compounds were also subjected to in silico study to predict their physiochemical properties and drug-likeness score.


Cancer Bile acid \(\alpha \)-cyanostilbene Anticancer Antibacterial 



The author RS would like to acknowledge Birla Institute of Technology and Science (BITS), Pilani, for providing additional research grant. The author DA is thankful to DST, New Delhi, for providing Senior Research Fellowship. We also like to thank central NMR facility BITS Pilani. The authors also sincerely acknowledge financial support from DST under FIST program [Project: SR/FST/CSI-270/2015] for HRMS facility.

Supplementary material

11030_2017_9797_MOESM1_ESM.docx (5.7 mb)
Supplementary material 1 (docx 5873 KB)


  1. 1.
    Chabner BA, Roberts TG (2005) Chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72. CrossRefPubMedGoogle Scholar
  2. 2.
    Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818–1822. CrossRefPubMedGoogle Scholar
  3. 3.
    Rosen H, Abribat T (2005) The rise and rise of drug delivery. Nat Rev Drug Discov 4:381–385. CrossRefPubMedGoogle Scholar
  4. 4.
    Mikov M, Fawcett J, Kuhajda K, Kevresan S (2006) Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur J Drug Metab Pharmacokinet 31:237–251. CrossRefPubMedGoogle Scholar
  5. 5.
    Segal NH, Saltz LB (2009) Evolving treatment of advanced colon cancer. Annu Rev Med 60:207–219. CrossRefPubMedGoogle Scholar
  6. 6.
    Saltz LB (2010) Adjuvant therapy for colon cancer. Surg Oncol Clin N Am 19:819–827. CrossRefPubMedGoogle Scholar
  7. 7.
    Mukhopadhyay S, Maitra U (2004) Chemistry and biology of bile acids. Curr Sci 87:1666–1683 ISSN 0011-3891Google Scholar
  8. 8.
    Tolle-Sander S, Lentz KA, Maeda DY, Coop A, Polli JE (2004) Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm 1:40–48. CrossRefPubMedGoogle Scholar
  9. 9.
    Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, Cheng RH, Wang L, Lam KS (2009) A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30:6006–6016. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sreekanth V, Bansal S, Motiani RK, Kundu S, Muppu SK, Majumdar TD, Panjamurthy K, Sengupta S, Bajaj A (2013) Design, synthesis, and mechanistic investigations of bile acid-tamoxifen conjugates for breast cancer therapy. Bioconjug Chem 24:1468–1484. CrossRefPubMedGoogle Scholar
  11. 11.
    Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, Roda A, Rita Di Biase A, Roda E, Simoni P, Colecchia A (2007) Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol 2:155–177. CrossRefPubMedGoogle Scholar
  12. 12.
    Choi YH, Im EO, Suh H, Jin Y, Yoo YH, Kim ND (2003) Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells. Cancer Lett 199:157–167. CrossRefPubMedGoogle Scholar
  13. 13.
    Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G (2005) Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97:846–853. CrossRefPubMedGoogle Scholar
  14. 14.
    Su-Bogyee W, Park BS, Kim JY, Soojinbaek Y, Seo SY, Lee SH, Kim JH, Hongsuksuh NDK, Lim YJ, Yoo YH (2005) Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo. Int J Oncol 27:653–659. CrossRefGoogle Scholar
  15. 15.
    Park SE, Choi HJ, Yee SB, Chung HY, Suh H, Choi YH, Yoo YH, Kim ND (2004) Synthetic bile acid derivatives inhibit cell proliferation and induce apoptosis in HT-29 human colon cancer cells. Int J Oncol 25:231–236. PubMedCrossRefGoogle Scholar
  16. 16.
    Im EO, Choi YH, Paik K-J, Suh H, Jin Y, Kim K-W, Yoo YH, Kim ND (2001) Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Lett 163:83–93. CrossRefPubMedGoogle Scholar
  17. 17.
    Choi YH, Im E-O, Suh H, Jin Y, Lee W, Yoo YH, Kim K-W, Kim N (2001) Apoptotic activity of novel bile acid derivatives in human leukemic T cells through the activation of caspases. Int J Oncol 18:979–984. PubMedCrossRefGoogle Scholar
  18. 18.
    Im E, Choi S-H, Suh H, Choi YH, Yoo YH, Kim ND (2005) Synthetic bile acid derivatives induce apoptosis through a c-Jun N-terminal kinase and NF-\(\kappa \)B-dependent process in human cervical carcinoma cells. Cancer Lett 229:49–57. CrossRefPubMedGoogle Scholar
  19. 19.
    Park SE, Lee SW, Hossain MA, Kim MY, Kim M-N, Ahn EY, Park YC, Suh H, Kim G-Y, Choi YH (2008) A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells. Cancer Lett 270:77–86. CrossRefPubMedGoogle Scholar
  20. 20.
    Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM (2008) Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer’s disease. Trends Mol Med 14:54–62. CrossRefPubMedGoogle Scholar
  21. 21.
    Brossard D, El Kihel L, Clément M, Sebbahi W, Khalid M, Roussakis C, Rault S (2010) Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines. Eur J Med Chem 45:2912–2918. CrossRefPubMedGoogle Scholar
  22. 22.
    Brossard D, Lechevrel M, El Kihel L, Quesnelle C, Khalid M, Moslemi S, Reimund J-M (2014) Synthesis and biological evaluation of bile carboxamide derivatives with pro-apoptotic effect on human colon adenocarcinoma cell lines. Eur J Med Chem 86:279–290. CrossRefPubMedGoogle Scholar
  23. 23.
    Agarwal DS, Anantaraju HS, Sriram D, Yogeeswari P, Nanjegowda SH, Mallu P, Sakhuja R (2016) Synthesis, characterization and biological evaluation of bile acid-aromatic/heteroaromatic amides linked via amino acids as anti-cancer agents. Steroids 107:87–97. CrossRefPubMedGoogle Scholar
  24. 24.
    Liu Y, Liu Y, Chen H, Yao X, Xiao Y, Zeng X, Zheng Q, Wei Y, Song C, Zhang Y (2015) Synthetic resveratrol derivatives and their biological activities: a review. Open J Med Chem 5:97–105. CrossRefGoogle Scholar
  25. 25.
    Tarleton M, Gilbert J, Robertson MJ, McCluskey A, Sakoff JA (2011) Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound. MedChemComm 2:31–37. CrossRefGoogle Scholar
  26. 26.
    Penthala NR, Sonar VN, Horn J, Leggas M, Yadlapalli JSK, Crooks PA (2013) Synthesis and evaluation of a series of benzothiophene acrylonitrile analogs as anticancer agents. MedChemComm 4:1073–1078. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T (1998) Novel combretastatin analogs effective against murine solid tumors: design and structure-activity relationships. J Med Chem 41:3022–3032. CrossRefPubMedGoogle Scholar
  28. 28.
    Penthala NR, Thakkar S, Crooks PA (2015) Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents. Bioorg Med Chem Lett 25:2763–2767.
  29. 29.
    Alam MS, Nam Y-J, Lee D-U (2013) Synthesis and evaluation of (Z)-2, 3-diphenylacrylonitrile analogs as anti-cancer and anti-microbial agents. Eur J Med Chem 69:790–797. CrossRefPubMedGoogle Scholar
  30. 30.
    Gomes CMF, van Paassen H, Romeo S, Welling MM, Feitsma R, Abrunhosa AJ, Botelho MF, Hogendoorn PC, Pauwels E, Cleton-Jansen AM (2006) Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. Nucl Med Biol 33:831–840. CrossRefPubMedGoogle Scholar
  31. 31.
    Molinspiration Cheminformatics, Nova ulica, SK-900 26 Slovensky Grob, Slovak Republic.
  32. 32.
    Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I (2002) Rate-limited steps of human oral absorption and QSAR studies. Pharm Res 19:1446–1457. CrossRefPubMedGoogle Scholar
  33. 33.
    Maximo da Silva M, Comin M, Santos Duarte T, Foglio MA, de Carvalho JE, do Carmo Vieira M, Nazari Formagio AS (2015) Synthesis, antiproliferative activity and molecular properties predictions of galloyl derivatives. Molecules 20:5360–5373. CrossRefGoogle Scholar
  34. 34.
    Molsoft LLC, 1199 Sorrento Valley Road, S209 San Diego CA 92121, USA.
  35. 35.
    Penthala NR, Zong H, Ketkar A, Madadi NR, Janganati V, Eoff RL, Guzman L, Crooks PA (2015) Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogs as antitubulin agents. Eur J Med Chem 92:212–220. CrossRefPubMedGoogle Scholar
  36. 36.
    Lai X-Z, Feng Y, Pollard J, Chin JN, Rybak MJ, Bucki R, Epand RF, Epand RM, Savage PB (2008) Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res 41:1233–1240. CrossRefPubMedGoogle Scholar
  37. 37.
    Parveen M, Malla AM, Alam M, Ahmad M, Rafiq S (2014) Stereoselective synthesis of Z-acrylonitrile derivatives: catalytic and acetylcholinesterase inhibition studies. New J Chem 38:1655–1667. CrossRefGoogle Scholar
  38. 38.
    Chowdhury R, Chowdhury S, Roychoudhury P, Mandal C, Chaudhuri K (2009) Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. Apoptosis 14:108–123.
  39. 39.
    Othman N, In LLA, Harikrishna JA, Hasima N (2013) Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SKLU1 human lung adenocarcinoma cells. PLoS ONE 8:e81735CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Agnihotri S, Mukherji S, Mukherji S (2014) Size-controlled silver nanoparticles synthesized over the range 5–100 nm using the same protocol and their antibacterial efficacy. RSC Adv 4:3974–3983. CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  • Devesh S. Agarwal
    • 1
  • Rajnish Prakash Singh
    • 2
  • K. Lohitesh
    • 2
  • Prabhat N. Jha
    • 2
  • Rajdeep Chowdhury
    • 2
  • Rajeev Sakhuja
    • 1
  1. 1.Department of ChemistryBirla Institute of Technology and SciencePilaniIndia
  2. 2.Department of Biological SciencesBirla Institute of Technology and SciencesPilaniIndia

Personalised recommendations